Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
RiverVest Venture Partners is a venture capital firm founded in September 2000, headquartered in St. Louis, Missouri, with additional offices in San Diego, California, and Cleveland, Ohio. The firm focuses on building life science companies that address significant unmet medical needs, aiming to deliver strong returns to its investors. RiverVest has raised a total of 8 funds with an aggregate AUM exceeding $1.6 billion, with the most recent fund, RiverVest Venture Fund V, closing at $275 million in March 2021.
Over its history, RiverVest has established a strong track record in the life sciences sector, with notable exits including Allakos, Mirum Pharmaceuticals, and Spruce Biosciences. The firm emphasizes early-stage investments in biopharmaceutical and medical device companies, particularly those with a clear path to clinical approval. RiverVest's Archer Seed Fund incubates new ventures from inception, further solidifying its commitment to fostering innovation in healthcare.
RiverVest Venture Partners primarily invests in early-stage biopharmaceutical and medical device companies. The firm targets sectors such as biotech and healthcare, focusing on products that address significant unmet medical needs. Their investment strategy includes leading financings, founding companies, and building strong investor syndicates. RiverVest seeks to support innovations that can significantly impact patient care and outcomes, emphasizing safety and efficacy in early clinical trials.
The firm invests across various stages, including seed, Series A, Series B, and growth equity. RiverVest's dual strategy involves founding companies through its Archer Seed Fund while also investing in select later-stage opportunities to diversify its portfolio. This approach allows RiverVest to effectively manage risk while achieving high hit rates in their investments.
RiverVest Venture Partners has a diverse portfolio of 61 companies, primarily in the life sciences sector. Notable portfolio companies include:
In addition to these current investments, RiverVest has achieved notable exits, including Good Therapeutics, acquired by Roche for $250 million in 2022, and Standard Bariatrics, acquired by Teleflex for $170 million plus additional milestone payments in 2022. The firm has a strong focus on companies that can deliver significant advancements in patient care.
Jay W. Schmelter: Co-Founder & Managing Director. Jay has extensive experience in venture capital and has been instrumental in leading investments in the life sciences sector.
John McKearn: Senior Advisor. John brings a wealth of knowledge in biopharmaceuticals and has played a key role in guiding portfolio companies.
Niall O'Donnell: Managing Director. Niall has a strong background in healthcare investments and has led several successful funding rounds.
Tom Melzer: Co-Founder and Managing Director. Tom has a deep understanding of the life sciences market and has been involved in numerous successful exits.
Derek Rapp: Managing Director. Derek specializes in medical devices and has a proven track record in the industry.
Karen Spilizewski: Managing Director. Karen has extensive experience in venture capital and focuses on early-stage investments.
Isaac Zike: Managing Director. Isaac has a strong background in healthcare and has been involved in various successful investments.
Pascal Krotee: Principal. Pascal focuses on identifying promising investment opportunities in the life sciences sector.
Nafise Masoumi: Principal. Nafise has a background in healthcare investments and supports portfolio companies in their growth.
Michael Berman: Consultant and Venture Partner. Michael provides strategic insights and guidance to portfolio companies.
Sivan Weitzman: Chief Financial Officer. Sivan manages the financial operations of the firm.
Courtney Harris: Controller. Courtney oversees financial reporting and compliance.
Andrew Kleiboeker: Associate. Andrew supports the investment team in due diligence and research.
Jeff Seitz: Senior Analyst. Jeff conducts market analysis and supports investment decisions.
Brandon Cohen: Analyst. Brandon assists in research and analysis for potential investments.
Poppy Keller: Consultant. Poppy provides insights into market trends and opportunities.
Corrin Short: Executive Assistant. Corrin supports the team with administrative tasks.
To pitch RiverVest Venture Partners, founders should send an email to info@rivervest.com. It is important to include a comprehensive pitch deck that outlines the business model, market opportunity, product development stage, and team background. RiverVest appreciates detailed information that demonstrates a clear understanding of the market and the competitive landscape.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
RiverVest operates several funds, including the RiverVest Venture Fund I, II, III, and IV, which focus on life sciences investments. Additionally, the firm manages the Archer Seed Fund, a $15 million fund aimed at early-stage biopharmaceutical companies. This fund is designed to incubate new ventures from inception, providing essential support and resources to founders in the life sciences sector.
In December 2025, RiverVest Venture Partners announced that Bluejay Therapeutics, a portfolio company, entered a definitive acquisition agreement with Mirum Pharmaceuticals. This acquisition highlights RiverVest's successful track record in identifying and nurturing promising life sciences companies.
In 2022, RiverVest achieved notable exits with Good Therapeutics being acquired by Roche for $250 million upfront and Standard Bariatrics being acquired by Teleflex for $170 million plus additional milestone payments. These exits underscore the firm's ability to generate significant returns for its investors.
RiverVest has also been active in sharing insights through their blog, with posts including a February newsletter and a recap of the JPM 2026 conference, reflecting ongoing engagement with the life sciences community.
What are RiverVest's investment criteria?
RiverVest primarily invests in early-stage biopharmaceutical and medical device companies that address significant unmet medical needs. The firm looks for products with a clear path to clinical approval and a strong potential for impact on patient care.
How can I apply or pitch to RiverVest?
Founders can reach out to RiverVest via email at info@rivervest.com to initiate a pitch. It is advisable to include a detailed overview of the business model, market opportunity, and product development stage in the pitch.
What makes RiverVest different from other venture capital firms?
RiverVest's focus on life sciences, combined with its dual strategy of founding companies through the Archer Seed Fund and investing in later-stage opportunities, sets it apart. The firm also emphasizes building strong investor syndicates and providing strategic guidance to portfolio companies.
What is RiverVest's geographic scope?
RiverVest primarily invests in North America, focusing on companies that are developing innovative solutions in the biotech and healthcare sectors.
What is RiverVest's post-investment involvement like?
RiverVest adds value to its portfolio companies by leveraging its extensive network in the life sciences sector, providing strategic guidance, and facilitating access to research from leading academic and clinical institutions across the US. The firm also supports its companies through the Archer Seed Fund, which incubates new ventures from inception.
What is the typical check size for investments?
While specific check sizes are not disclosed, RiverVest typically invests in early-stage rounds, which can range from seed funding to larger Series A and B rounds, aligning with their focus on building life science companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.